These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26268714)

  • 1. Economic impact of a modification of the treatment trajectories of patients with end-stage renal disease.
    Couchoud C; Couillerot AL; Dantony E; Elsensohn MH; Labeeuw M; Villar E; Ecochard R; Bongiovanni I
    Nephrol Dial Transplant; 2015 Dec; 30(12):2054-68. PubMed ID: 26268714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of various strategies of end-stage renal disease patients' care in France].
    Bongiovanni I; Couillerot-Peyrondet AL; Sambuc C; Dantony E; Elsensohn MH; Sainsaulieu Y; Ecochard R; Couchoud C
    Nephrol Ther; 2016 Apr; 12(2):104-15. PubMed ID: 26915892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
    Zhang H; Zhang C; Zhu S; Ye H; Zhang D
    BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling treatment trajectories to optimize the organization of renal replacement therapy and public health decision-making.
    Couchoud C; Dantony E; Elsensohn MH; Villar E; Ecochard R;
    Nephrol Dial Transplant; 2013 Sep; 28(9):2372-82. PubMed ID: 23787553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.
    Mohnen SM; van Oosten MJM; Los J; Leegte MJH; Jager KJ; Hemmelder MH; Logtenberg SJJ; Stel VS; Hakkaart-van Roijen L; de Wit GA
    PLoS One; 2019; 14(8):e0220800. PubMed ID: 31415578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.
    Couillerot-Peyrondet AL; Sambuc C; Sainsaulieu Y; Couchoud C; Bongiovanni-Delarozière I
    Eur J Health Econ; 2017 May; 18(4):459-469. PubMed ID: 27146313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding cost of care for patients on renal replacement therapy: looking beyond fixed tariffs.
    Li B; Cairns JA; Fotheringham J; Tomson CR; Forsythe JL; Watson C; Metcalfe W; Fogarty DG; Draper H; Oniscu GC; Dudley C; Johnson RJ; Roderick P; Leydon G; Bradley JA; Ravanan R
    Nephrol Dial Transplant; 2015 Oct; 30(10):1726-34. PubMed ID: 26071229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
    Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
    Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of renal replacement therapies in Finland.
    Salonen T; Reina T; Oksa H; Sintonen H; Pasternack A
    Am J Kidney Dis; 2003 Dec; 42(6):1228-38. PubMed ID: 14655195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
    Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
    Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricted mean survival time over 15 years for patients starting renal replacement therapy.
    Couchoud C; Dantony E; Elsensohn MH; Villar E; Vigneau C; Moranne O; Rabilloud M; Ecochard R
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii60-ii67. PubMed ID: 28057870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators.
    van de Luijtgaarden MW; Jager KJ; Stel VS; Kramer A; Cusumano A; Elliott RF; Geue C; MacLeod AM; Stengel B; Covic A; Caskey FJ
    Nephrol Dial Transplant; 2013 May; 28(5):1264-75. PubMed ID: 23543592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation].
    Blotière PO; Tuppin P; Weill A; Ricordeau P; Allemand H
    Nephrol Ther; 2010 Jul; 6(4):240-7. PubMed ID: 20554257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends of cost and mortality of patients on haemodialysis with end stage renal disease.
    Chang YK; Hsu CC; Chen PC; Chen YS; Hwang SJ; Li TC; Huang CC; Li CY; Sung FC
    Nephrology (Carlton); 2015 Apr; 20(4):243-9. PubMed ID: 25516387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
    Hruskova Z; Pippias M; Stel VS; Abad-Díez JM; Benítez Sánchez M; Caskey FJ; Collart F; De Meester J; Finne P; Heaf JG; Magaz A; Palsson R; Reisæter AV; Salama AD; Segelmark M; Traynor JP; Massy ZA; Jager KJ; Tesar V
    Am J Kidney Dis; 2019 Feb; 73(2):184-193. PubMed ID: 30122544
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.